Business Context and Reporting Period
This Form 8-K is a current report filed by Aprea Therapeutics, Inc. on July 23, 2026. The registrant is a Delaware corporation with its principal executive offices in Doylestown, PA. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol APRE. The filing addresses a specific regulatory event regarding the company's continued listing status.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and listing compliance matters.
Material Changes and Listing Status
The primary material event reported is the extension of a compliance period regarding the Nasdaq Minimum Bid Price Requirement:
- Deficiency: The company failed to maintain the required minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
- Initial Notice: A deficiency notice was previously issued on January 23, 2026, granting an initial 180-day compliance period ending July 22, 2026.
- Extension Granted: On July 23, 2026, Nasdaq granted an additional 180-day "Second Compliance Period" extending until January 19, 2027.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during the Second Compliance Period.
Outlook, Risks, and Contingencies
Delisting Risk: If the company fails to demonstrate compliance by January 19, 2027, Nasdaq will provide written notification that the Common Stock will be delisted. The company retains the right to appeal such a determination to a hearings panel.
Management Commentary: The filing contains no forward-looking financial guidance or operational commentary beyond the procedural details of the listing extension.
Investor Verification Checklist
- Verify the current trading price of APRE to assess the likelihood of meeting the $1.00 bid price threshold.
- Monitor the stock's closing bid price daily to track progress toward the 10 consecutive business days requirement.
- Review future filings for any updates on the company's capital structure or potential reverse stock splits, which are common strategies to address bid price deficiencies.
- Confirm the exact deadline of January 19, 2027, for the final compliance determination.